Compare DexCom, Inc. (DXCM) vs iShares JPMorgan USD Emerging Markets Bond ETF (EMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares JPMorgan USD Emerging Markets Bond ETF — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.59 (market cap $12.79B). The key difference: DexCom, Inc. is far larger — about 2.5× iShares JPMorgan USD Emerging Markets Bond ETF's market cap, and DexCom, Inc. is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days on average.
| DXCM | EMB | |
|---|---|---|
Market Cap | $31.81B | $12.79B |
Volume | 2,861,821 | 8,552,536 |
Sector | Health | Fixed Income |
52-Week High | $92.34 | $97.74 |
52-Week Low | $54.84 | $90.14 |
Typical Hold Time | 62 Days | 50 Days |
Enterprise Value | $31.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
EMB trades at $90.78, down 0.19% with a bearish technical signal from moving averages. The stock shows mixed momentum with RSI indicators suggesting potential oversold conditions at lower timeframes. Recent corporate actions include scheduled dividend payments through late 2026, though key valuation and profitability metrics remain unavailable for analysis.
The outlook remains cautious with technical indicators favoring bearish momentum. Investment appeal may center on future dividend income given the lack of current fundamental data. Primary risks include market volatility and the absence of transparent financial metrics for proper valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →
